Case 1, a 10-year-old, F508del-homozygous female, had a 3.5-year history of persistent M. abscessus colonisation. Nodular infiltrates and clinical decline prompted intravenous amikacin, intravenous cefoxitin and oral linezolid for 2 years. Cefoxitin was discontinued after 1 month due to rash, despite an attempt at cefoxitin desensitisation. Ototoxicity due to intravenous amikacin was noted after 4 months so this was replaced with aerosolised Amikacin. Despite linezolid (intravenous) and amikacin (inhaled) therapy, pulmonary function and body mass declined, and bronchoalveolar lavage (BAL) specimens returned smear positive results for many organisms and heavy growth of M. absessus. The organism exhibited intermediate sensitivity to amikacin and cefoxitin, while it was sensitive to linezolid. Aerosolised GM-CSF (Sargramostim (Genezyme, Cambridge, MA, USA); 250 μg twice daily, diluted in 2 cm 3 saline) was added and administered on alternate weeks as previously described [8] via a Pari LC nebuliser (Pari, Midlothian, VA, USA). There was clinical improvement and a decrease in radiological opacities within areas of extensive varicoid and cystic bronchiectasis (table 1). GM-CSF was continued and antibiotics were discontinued after 3 months. After the patient remained off antibiotics for 3 months, a decision was made to recombine aerosolised GM-CSF with linezolid (intravenous) and amikacin (inhaled). After 4 months of combined therapy, both acid-fast bacillus (AFB) smear and cultures became negative (figure 1). She remains on inhaled GM-CSF alone. GM-CSF 250 μg twice daily, 1 week on 1 week off, was begun without antibiotic therapy. Clinical improvement was noted without toxicity (table 1). After 6 months of GM-CSF, sputum smears became negative and culture burden decreased to one colony per plate (figure 1).
Discrepancy between in vitro antibiotic susceptibility and clinical response to treatment of MABSC infection suggests that factors involving the innate immune system may play a role. There is one case report using subcutaneous administration of GM-CSF. MOSER et al. [10] administered GM-CSF at 2 μg·kg −1 ·day −1 subcutaneously for ∼1 year in two CF patients with M. abscessus infection that was resistant to antibiotic treatment. The treatment was well tolerated. One patient improved and was taken off the lung transplant list, while the other patient stabilised. However, use of aerosolised GM-CSF for the treatment of infections in humans has not been reported. Inhaled GM-CSF increases the number and function of phagocytic cells obtained from BAL [11] . GM-CSF is expressed constitutively in human airway epithelium [12] . Although human CF airway epithelial cell release of basal and stimulated GM-CSF is not different from control airway epithelial cells [13] , and both Pseudomonas aeruginosa and Staphylococcus aureus increase GM-CSF expression [14] in cultured CF airway epithelial cells, BAL concentrations of GM-CSF in CFTR −/− mice [15] and in sputa of CF patients are significantly decreased [16] . Moreover, the airway concentrations of GM-CSF are lesser in CF patients during respiratory exacerbation and are undetectable in those sensitised to Aspergillus fumigatus [16] . Human CF alveolar macrophages do not have any intrinsic dysfunction or reduced capacity to generate reactive oxygen species [17] or to synthesise cytokines [15] . Taken together, we hypothesise that CF macrophages can respond to GM-CSF but that GM-CSF activity is reduced in the airway and alveolus, perhaps due to impaired diffusion of epithelially released GM-CSF in bronchiectatic airways or physical and chemical properties of abnormal CF sputum.
In summary, we report two CF patients with evidence of M. abscessus colonization, one with lack of response to aminoglycosides and/or linezolid, in whom aerosolized GM-CSF was well tolerated with 
